The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain
- PMID: 25697597
- PMCID: PMC4411215
- DOI: 10.1016/j.neulet.2015.01.084
The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain
Abstract
Fabry disease is an X-linked lysosomal storage disorder characterised by accumulation of glycosphingolipids, and accompanied by clinical manifestations, such as cardiac disorders, renal failure, pain and peripheral neuropathy. Globotriaosylsphingosine (lyso-Gb3), a deacylated form of globotriaosylceramide (Gb3), has emerged as a marker of Fabry disease. We investigated the link between Gb3, lyso-Gb3 and pain. Plantar administration of lyso-Gb3 or Gb3 caused mechanical allodynia in healthy mice. In vitro application of 100nM lyso-Gb3 caused uptake of extracellular calcium in 10% of sensory neurons expressing nociceptor markers, rising to 40% of neurons at 1μM, a concentration that may occur in Fabry disease patients. Peak current densities of voltage-dependent Ca(2+) channels were substantially enhanced by application of 1μM lyso-Gb3. These studies suggest a direct role for lyso-Gb3 in the sensitisation of peripheral nociceptive neurons that may provide an opportunity for therapeutic intervention in the treatment of Fabry disease-associated pain.
Keywords: Calcium imaging; Dorsal root ganglia; Fabry disease; Pain; Voltage-dependent Ca(2+) channels.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Figures




Comment in
-
Pain in Fabry disease: Plasma lipids sensitise nociceptors.Neurosci Lett. 2015 May 6;594:161-2. doi: 10.1016/j.neulet.2015.02.056. Epub 2015 Feb 25. Neurosci Lett. 2015. PMID: 25725170 No abstract available.
References
-
- Fabry H. Angiokeratoma corporis diffusum–Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr. 2002;91:3–5. - PubMed
-
- Kaye E.M., Kolodny E.H., Logigian E.L., Ullman M.D. Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann. Neurol. 1988;23:505–509. - PubMed
-
- Møller A.T., Jensen T.S. Neurological manifestations in Fabry’s disease. Nat. Clin. Pract. Neurol. 2007;3:95–106. - PubMed
-
- Dütsch M., Marthol H., Stemper B., Brys M., Haendl T., Hilz M.J. Small fiber dysfunction predominates in Fabry neuropathy. J. Clin. Neurophysiol. 2002;19:575–586. - PubMed
-
- Mills K., Morris P., Lee P., Vellodi A., Waldek S., Young E., Winchester B. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J. Inherit. Metab. Dis. 2005;28:35–48. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous